Fragment, CJC1295, Ipamorelin 12mg (Blend)

HGH Fragment 176-191 6mg, CJC1295 3mg, Ipamorelin 3mg (12mg Total Blend)

75.00 USD

Availability: In stock

  • Buy 3 for $72.50 each and save 4%
  • Buy 5 for $70.00 each and save 7%
  • Buy 10 for $68.50 each and save 9%

FREE Shipping for orders over $200 (USA Only)

$15.00 Flat Rate Shipping Worldwide (Most Countries) 

*Includes one 30mL Bacteriostatic Water with orders over $300.00

Fragment, CJC1295, Ipamorelin 12mg (Blend)

Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

Fragment 176-191 is a small section of human growth hormone sequence (hGH) that has been shown in animal models to enhance fat burning and shift metabolism toward the maintenance of lean body mass[1]–[3]. Research also suggests that fragment 176-191 also lacks many of the side effects caused by hGH such as decreased insulin sensitivity, long-bone growth, and edema. That said, the fragment could contribute to the normal physiologic mechanisms that control GH secretion and could therefore positively affect levels of GH according to recent research studies.

CJC-1295 could counteract the GH effects of fragment 176-191 as it is a synthetic growth hormone releasing hormone and therefore stimulates the release of G[4]. CJC-1295 acts to increase basal and peak levels of GH and has also been shown to increase free plasma levels of GH. Only free GH is biologically active. CJC-1295 can therefore compensate for a normal physiologic response to fragment 176-191. This would allow for the benefits of fragment 176-191 to be realized without having any impact on normal GH secretion.

To further boost GH secretion above basal levels and to particularly affect peak GH secretion, Ipamorelin could be added to the mix. Ipamorelin is a growth hormone secretagogue receptor agonist that has been shown in animal studies to have potent and specific effects on GH secretion while having very limited side effects[5]. Ipamorelin has also been shown to be highly beneficial to bone mineralization and insulin control in animal models[6], [7]. Ipamorelin is a short-acting peptide whereas CJC-1295 is a longer-acting peptide. The former provides rapid onset GH release while the latter acts to raise GH secretion over longer periods and maintain normal physiologic secretion patterns[8], [9].

About The Author

Research by L. Edmiston, M.D. for Peptide Sciences. L. Edmiston holds an M.D. from Case Western Reserve University School of Medicine and a B.S. in molecular biology.


  • [1] M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. [PubMed]
  • [2] R. Ferrer-Lorente, C. Cabot, J.-A. Fernández-López, and M. Alemany, “Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats,” Life Sci., vol. 77, no. 16, pp. 2051–2058, Sep. 2005. [PubMed]
  • [3] F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. [PubMed]
  • [4] M. C. Van Hout and E. Hearne, “Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions,” Subst. Use Misuse, vol. 51, no. 1, pp. 73–84, Jan. 2016. [PubMed]
  • [5] K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]
  • [6] E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
  • [7] J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]
  • [8] M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]
  • [9] M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]